Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · prior close shown (market closed)
VYNE Therapeutics Inc. shows recovering business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Revenue -65% YoY in Q2 FY2025.
2 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
Reported figures for VYNE Therapeutics Inc. — research only, not investment advice.
Updated
What happened recently for VYNE Therapeutics Inc. (VYNE) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
Prior close
$28.56
Market cap
$76.25M
Profitable
No
Revenue $70,000.00
Net income
$-5.75M
FY Aug 15, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for VYNE Therapeutics Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected companies and research pages from the AlphaOS knowledge graph.
Follow VYNE Therapeutics Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.